Overview of CRISPR
CRISPR represents a groundbreaking technology that’s reshaping lives and creating significant impacts in the field of medicine. The acronym CRISPR, which stands for “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—tiny, single-celled organisms devoid of organelles. These sequences reside within the genomes of prokaryotes, which organize a cell’s DNA in clusters.
Serving as a tool for gene editing, CRISPR modifies specific areas of DNA to address serious health conditions. Its effectiveness is noteworthy as it aids the body’s defense against viral attacks by integrating the foreign DNA into its genome, enabling it to identify and eliminate the virus in subsequent instances. What stands out is that, in contrast to other gene editing methods, CRISPR is significantly more accurate and simpler to program, facilitating an easier process for redesigning sequences. While traditional gene-editing tools often employ a single protein, CRISPR utilizes RNA-guided targeting alongside the Cas9 enzyme.
Mechanism of CRISPR
CRISPR operates by utilizing a natural defense mechanism present in bacteria, allowing them to detect and eliminate viral threats. When a virus infiltrates a bacterial cell (a prokaryote), the bacterium retains a part of the invader’s DNA within its genome as a genetic “memory.” This process enables the bacterium to recognize and respond more efficiently to subsequent infections.
In the realm of gene editing, this system is modified with two essential components: the Cas9 enzyme, which acts like molecular scissors to sever DNA, and guide RNA, which directs Cas9 to the exact genetic sequence requiring modification. Once the specific DNA is cut, the cell’s innate repair mechanisms take over, allowing scientists to implement changes to the genetic code.
Unlike previous tools that depended on challenging-to-reprogram proteins, CRISPR’s RNA-guided system offers greater flexibility, simplicity in design, and superior precision. This ease of use and reliability have enabled CRISPR to be utilized in various fields, including medicine, agriculture, manufacturing, and microbiology—such as tailoring microbes to enhance product yields. However, as this article examines, increased capabilities bring forth escalating ethical concerns, especially regarding germline editing and genetic enhancement.
First Patient to Receive Personalized CRISPR Treatment
In February 2025, the first personalized CRISPR treatment in the world was administered to an infant named KJ to address a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme crucial for converting ammonia (produced during protein metabolism) into urea. A team spearheaded by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia developed this therapy following extensive research in gene editing and cooperation with various other clinicians.
Their research concentrated on disorders impacting the urea cycle, leading to a toxic accumulation of ammonia that damages organs such as the brain and liver. They customized the treatment specifically for KJ’s variant of CPS1 deficiency using prior research on comparable conditions.
To date, the only CRISPR treatments sanctioned by the U.S. FDA have been for more prevalent conditions such as sickle cell anemia and beta thalassemia, affecting tens of thousands or more individuals. In KJ’s situation, his treatment was formulated within six months of his birth, targeting his unique CPS1 variant. The team developed a base editing therapy that would be delivered to his liver via lipid nanoparticles to rectify the defective enzyme.
The treatment administered in February was the first of three doses; KJ received the subsequent doses in March and April 2025. As of his most recent dose, he has shown no significant side effects, demonstrates improved tolerance to dietary protein, and requires reduced medication to regulate ammonia levels. Although continued monitoring will be necessary, Ahrens-Nicklas mentions that the outcomes so far are encouraging.
CRISPR’s Ethical Implications
Just like any innovative technology, CRIS